Anti-Inflammatories: Small Molecule Approaches
Focusing on Medicinal Chemistry Optimizations
April 23-24, 2014
Biologics have been useful in treating diseases of chronic inflammation such as multiple sclerosis or rheumatoid arthritis, but there is still an unmet medical need for more convenient and safer treatment options for such diseases. A few kinase inhibitors that fit these criteria have been recently launched and a few are in late-stage development. Join fellow drug discovery scientists at Cambridge Healthtech Institute’s fifth annual Anti-Inflammatories: Small Molecule Approaches day- and-a-half meeting track to stay abreast of the latest progress in the field of oral-based (mostly small molecules) inhibitors for inflammation. A focus will be on the chemical optimizations that have enabled the leading inflammation drug candidates to progress. Presentations on newer and non-kinase targets for combating inflammation will also be a part of the agenda.
Seng-Lai “Thomas” Tan, Ph.D., Head, Cellular and Translational Immunology, EMD Serono Research and
Development Institute, Inc.
A Novel Class of Selective SYK Inhibitors for Inflammation
Lars Burgdorf, Ph.D., Principal Scientist, Medicinal Chemistry, Merck KGaA
Epigenetic BET Inhibitors and Inflammation
Gerald Denis, Ph.D., Associate Professor, Cancer Center, Boston University School of Medicine
Novel Small Molecular Ligands of KEAP1 Induce Protective NRF2-Dependent Anti-Inflammatory Responses in Neurodegenerative Models
Aleksey Kazantsev, Ph.D., Associate Professor, Neurology, Harvard Medical School and Massachusetts General Hospital
Targeting the Immunoproteasome
Dustin McMinn, Ph.D., Associate Director, Medicinal Chemistry, Onyx Pharmaceuticals
Selective JAK1 Inhibition as a Therapeutic Strategy in Inflammation
Christel Menet, Ph.D., Senior Lead, Project Director, Autoimmune Disease, Galapgos
B-Cell Receptor Signaling Inhibitors for Treatment of Inflammatory Diseases
Kamal Puri, Ph.D., Associate Director, Research, Gilead Sciences, Inc.
Disrupting NRF2 and Keap1 Protein Interaction with Non-Covalent Inhibitors
Laura Silvian, Ph.D., Principal Scientist, Physical Biochemistry, Biogen Idec
Talk Title to be Announced
Jennifer Venable, Ph.D., Principal Scientist, Immunology Chemistry, Johnson & Johnson Pharmaceutical R&D